1. Sanofi (9 from 1,451 patents)

2. Other (3 from 832,680 patents)

3. Sanofi-aventis (3 from 389 patents)

4. Aventis Pharma S.a. (3 from 377 patents)

5. Sanofi-a Ventis Deutschland Gmbh (1 from 1,827 patents)

6. Aventis Pharmaceuticals Inc. (1 from 207 patents)

7. Selectide Corporation (1 from 10 patents)

8. Patek, Marcel (0 patent)

9. Lebl, Michal (0 patent)

1. 9328071 - Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals

2. 9073853 - Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists

3. 9018383 - Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals

4. 8802720 - Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals

5. 8618304 - Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals

6. 8501981 - CXCR2 inhibitors

7. 8445530 - Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals

8. 8420824 - Substituted pyrazoles, compositions containing these, method of production and use

9. 8410286 - Substituted pyrazoles, compositions containing these, method of production and use

10. 8362073 - Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals

11. 8058290 - 7-substituted aza-indazoles, compositions containing same, production method and use thereof

12. 7989439 - Substituted pyrazoles, compositions containing these, method of production and use

13. 7910602 - Pyrazolopyridine derivatives as inhibitors of β-Adrenergic receptor kinase 1

14. 7825115 - Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors

15. 7354933 - Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors